-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓Börse SIX Swiss Exchange ZürichISIN CH0012005267-
NovartisBörse SIX Swiss Exchange ZürichISIN CH0012005267 WKN: 904278Symbol NOVN.SW
-
NovartisBörse Börse MünchenEURSymbol NOTA
-
NOVARTIS AG-REGBörse Gettex System der Börse MünchenEURSymbol NOT
-
NOVARTIS AG-REGBörse Börse DüsseldorfEURSymbol NOT
-
NOVARTIS AG-REGBörse Börse StuttgartEURSymbol NOT
-
NOVARTIS AG-REGBörse Börse MünchenEURSymbol NOT
-
NOVARTIS AG-REGBörse Börse FrankfurtEURSymbol NOT
-
NovartisBörse Quotrix System der Börse DüsseldorfEURSymbol NOTA
-
NovartisBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol NOTA
-
NovartisBörse Gettex System der Börse MünchenEURSymbol NOTA
-
NOVARTIS AG-REGBörse Quotrix System der Börse DüsseldorfEURSymbol NOT
-
NovartisBörse Börse DüsseldorfEURSymbol NOTA
-
NovartisBörse Börse StuttgartEURSymbol NOTA
-
NOVARTIS AG-REGBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol NOT
-
NOVARTIS AG-REGBörse Börse BerlinEURSymbol NOT
-
NOVARTIS AG-REGBörse Börse HamburgEURSymbol NOT
-
NovartisBörse NYSE New York Stock ExchangeISIN US66987V1098 WKN: 907122USDSymbol NVS
-
ISIN CH0012005267 WKN: 904278USDSymbol NOVN
-
NovartisBörse BVMF
-
NovartisBörse London Stock Exchange
-
Symbol NOTA
-
Symbol NOTA
-
CHF
-
MXN
-
USD
-
NovartisBörse Bolsa de Comercio de Buenos Aires
-
ISIN CH0012005267
WKN 904278
Symbol NOVN.SW
Börse
SIX Swiss Exchange Zürich Zeitzone: Europe/Berlin
Firmenname
Novan, Inc
Marktkapitalisierung
118.240.562.752 (+- 54%)
Die einen sagen so, die anderen so... Es gibt 3 Datenquellen:
218.646.976 oder 172.940.000.000 oder 181.563.041.280
Mitarbeiter
54.012 (+- 100%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
23 oder 108.000 Mitarbeiter
Anzahl Aktien
2.265.008.000
KGV
17.9
EBITDA -24.745.000
Buchwert 0.02
Zahlte zuletzt am 04.03.2021 eine Dividende von 3 CHF . Seit damals wurde keine Dividende mehr ausgeschüttet Übersicht
Die Dividendenrendite
entsprach 3,50 % p. a.
beim aktuellen Kurs von 78,77 CHF +0,12%
Novartis underperformed den DAX um -54 % (+36 % Dividenden) vom 30.09.2013 bis 15.09.2021
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 78,77 CHF +0,12%
Letzte Communitymeinungen
- Ein User war zuletzt bullisch
- Im Alpha-Tester Battle 2021
-
Jen
Ein User hat Novartis abonniert.
Aktionärsstruktur der Novan, Inc
Portrait der Novartis Aktie
Das Unternehmen Novan, Inc aus Schweiz beschäftigt 54.012 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Pharmazeutika, Medizinische Produkte / Medizintechnik, Biotechnologie, Pharma tätig.
Die Novartis Aktie hat inklusive der Dividendenausschüttungen seit dem 30.09.2013 eine Gesamtrendite von 64% erwirtschaftet
Das Unternehmen Novan, Inc ist in mehr als 80 ETFs enthalten und somit ein eher allgemein bekannter Wert. Der Spitzenreiter UBS ETF (CH) SMI® gewichtet Novartis mit 16,90% im ETF.
Es ist auch möglich über Anleihen zu investieren. Hier findest du alle Novartis Anleihen auf einen Blick.
Entdecke die 6 ETFs in denen Novan, Inc am höchsten gewichtet ist Insgesamt in 80 ETFs enthalten
Dir gefallen die Informationen zu Novartis?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Novartis?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Novartis?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Novartis?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
218 News & Informationen zur Novartis Aktie
Artios raises USD153m in Series C financing
Arix Bioscience PLC
Artios raises USD153m in Series C financing
27-Jul-2021 / 07:02 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible… | July 27, 2021
Eye Care Surgical Devices Market to Grow by USD 3.49 Billion| Key Drivers, Opportunities and Market Forecasts|17000+ Technavio Research Reports
/PRNewswire/ — The eye care surgical devices market is poised to grow by USD 3.49 billion during 2021-2025, progressing at a CAGR of 5.86% during the forecast…
Eye Care Surgical Devices Market to Grow by USD 3.49 Billion| Key Drivers, Opportunities and Market Forecasts|17000+ Technavio Research Reports
/PRNewswire/ — The eye care surgical devices market is poised to grow by USD 3.49 billion during 2021-2025, progressing at a CAGR of 5.86% during the forecast…
Eye Care Surgical Devices Market to Grow by USD 3.49 Billion| Key Drivers, Opportunities and Market Forecasts|17000+ Technavio Research Reports
/PRNewswire/ — The eye care surgical devices market is poised to grow by USD 3.49 billion during 2021-2025, progressing at a CAGR of 5.86% during the forecast…
Eye Care Surgical Devices Market to Grow by USD 3.49 Billion| Key Drivers, Opportunities and Market Forecasts|17000+ Technavio Research Reports
/PRNewswire/ — The eye care surgical devices market is poised to grow by USD 3.49 billion during 2021-2025, progressing at a CAGR of 5.86% during the forecast…
Eye Care Surgical Devices Market to Grow by USD 3.49 Billion| Key Drivers, Opportunities and Market Forecasts|17000+ Technavio Research Reports
/PRNewswire/ — The eye care surgical devices market is poised to grow by USD 3.49 billion during 2021-2025, progressing at a CAGR of 5.86% during the forecast…
Eye Care Surgical Devices Market to Grow by USD 3.49 Billion| Key Drivers, Opportunities and Market Forecasts|17000+ Technavio Research Reports
/PRNewswire/ — The eye care surgical devices market is poised to grow by USD 3.49 billion during 2021-2025, progressing at a CAGR of 5.86% during the forecast…
Eye Care Surgical Devices Market to Grow by USD 3.49 Billion| Key Drivers, Opportunities and Market Forecasts|17000+ Technavio Research Reports
/PRNewswire/ — The eye care surgical devices market is poised to grow by USD 3.49 billion during 2021-2025, progressing at a CAGR of 5.86% during the forecast…
Eye Care Surgical Devices Market To Grow By USD 3.49 Billion| Key Drivers, Opportunities And Market Forecasts|17000 Technavio Research Reports
NEW YORK, July 26, 2021 /PRNewswire/ — The eye care surgical devices market is poised to grow by USD 3.49 billion during 2021-2025, progressing at a CAGR of
Novartis Leading in $10 Billion Market for New Cancer Treatment
GuruFocus Article or News written by Barry Cohen and the topic is about: FDA designates company's radiogland therapy a breakthrough
Skye Bioscience Appoints Biotech Executive Praveen Tyle, Ph.D. to Board of Directors
SAN DIEGO, CA, July 26, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing…
Cathie Wood’s ARK Invest Sells Over 2 Million Shares of KE Holdings – 24
One of Cathie Wood's Ark Invest funds sold over 2 million shares of KE Holdings on July 23.
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was s…
Cathie Wood’s ARK Invest Sells for 7
Here's a look at the ARK Invest Sells for July 23, 2021.
Global Biosimilar Monoclonal Antibodies (mAbs) Market in Pharmaceuticals Industry|Discover Company Insights in Technavio
NEW YORK, July 23, 2021 /PRNewswire/ — The biosimilar monoclonal antibodies (mAbs) market is poised to grow by USD 3.48 billion during 2021-2025,…
Global Antibody Market Expected to Reach USD 318,482.1 Million by 2027, With a CAGR Of 10.1% | Growth Market Reports
/PRNewswire/ — According to a recent market study published by Growth Market Reports, titled, “Global Antibody Market by Types, (Monoclonal Antibodies,…
Cathie Wood’s ARK Invest Sells Over 425,000 Shares of KE Holdings – 24
One of Cathie Wood's Ark Invest funds sold over 425,000 shares of KE Holdings on July 22.
NOVARTIS AG : Buy rating from UBS
In a research note published by Laura Sutcliffe, UBS advises its customers to buy the stock. The target price remains unchanged at CHF 96. | July 23, 2021
Bradley Mark J. Buys Workday Inc, Ritchie Bros Auctioneers Inc, Sells Verizon Communications Inc, Novartis AG
GuruFocus Article or News written by insider and the topic is about:
Hedge Funds Never Been Less Bullish On Novartis AG (NVS)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their…
NOVARTIS AG : Deutsche Bank is now Neutral
Deutsche Bank is less optimistic about the stock and is readjusting downwards his opinion. The broker's analyst Emmanuel Papadakis is now Neutral. The target price is lowered from CHF 100 to CHF 80. | July 22, 2021
Cathie Wood’s ARK Invest Sells Over 200,000 Shares of Pure Storage – 24
One of Cathie Wood's ARK Invest funds sold over 200,000 shares of Pure Storage on July 21.
NOVARTIS AG : Credit Suisse sticks Neutral
In a research note published by Jo Walton, Credit Suisse gives a Neutral rating to the stock. The target price continues to be set at CHF 90. | July 22, 2021
NOVARTIS AG : Goldman Sachs remains its Buy rating
Keyur Parekh from Goldman Sachs retains his positive opinion on the stock with a Buy rating. Previously set at CHF 110, the target price has been slightly modified to CHF 111. | July 22, 2021
Novartis' (NVS) Q2 Earnings Top Estimates as Businesses Recovers
Novartis (NVS) reports mixed results for the second quarter, as key brands maintain momentum and businesses show signs of recovery.
NOVARTIS AG : Bernstein sticks Neutral
Bernstein's research confirms his advice and maintains his neutral opinion on the stock. The target price remains set at CHF 92. | July 21, 2021
Novartis AG (NVS) CEO Vas Narasimhan on Q2 2021 Results – Earnings Call Transcript
Novartis AG (NYSE:NVS) Q2 2021 Earnings Conference Call July 21, 2021 8:00 a.m.
Novartis AG 2021 Q2 – Results – Earnings Call Presentation (NYSE:NVS)
The following slide deck was published by Novartis AG in conjunction with their 2021 Q2 earnings call.
Global Anti-Inflammatory Therapeutics Market to Reach $125.55 Billion by 2028: AMR
Rise in prevalence of autoimmune diseases and chronic respiratory conditions, advent of new drugs, and surge in adoption rate of anti-inflammatory drugs…
Global shares edge up ahead of key earnings – while concerns simmer over surge in Covid cases
Traders work on the floor of the New York Stock Exchange (NYSE) on December 07, 2018 in New York City Spencer Platt/Getty Images Global shares…
European Stocks Higher; Next Shines With Lifted Profit Guidance By Investing.com
European Stocks Higher; Next Shines With Lifted Profit Guidance
Novartis : Q2 2021 results Media release English
Ad hoc announcement pursuant to Art. 53 LR
Novartis International AG
Novartis Global Communications
CH-4002 Basel
… | July 21, 2021
NOVARTIS AG : Jefferies reiterates its Buy rating
Already positive, the research from Jefferies and its analyst Peter Welford still consider the stock as a Buy opportunity. The target price remains set at CHF 100. | July 21, 2021
Marketmind: A rocky road By Reuters
Marketmind: A rocky road
European Stock Futures Mixed; Earnings Season Continues By Investing.com
European Stock Futures Mixed; Earnings Season Continues
Novartis EPS beats by $0.17, beats on revenue (NYSE:NVS)
Novartis (NVS): Q2 Non-GAAP EPS of $1.66 beats by $0.17; GAAP EPS of $1.29 beats by $0.18.Revenue of $12.96B (+14.2% Y/Y) beats by $550M.“Novartis delivered a strong second quarter,…
JBJ Investment Partners, LLC Buys Vanguard Short-Term Inflation-Protected Securities, Vanguard Tax-Exempt Bond ETF, Vanguard Total Bond Market ETF, Sells Vanguard Short-Term Government Bond ETF, Domin
GuruFocus Article or News written by insider and the topic is about:
Novartis Q2 2021 Earnings Preview (NYSE:NVS)
Novartis (NYSE:NVS) is scheduled to announce Q2 earnings results on Wednesday, July 21st, before market open.The consensus EPS Estimate is $1.49 (+9.6% Y/Y) and the consensus…
Cathie Wood’s ARK Invest Sells Over 1.8 Million Shares of Pure Storage – 24
One of Cathie Wood's Ark Invest funds sold over 1.8 million shares of Pure Storage on July 19.
Doing Battle on (At Least) Two Fronts: What Happens When Multiple Regulators Engage in Parallel Enforcement Efforts?
Information gathered in civil proceedings is often used in subsequent criminal trials. But cooperation has its benefits as well.